@darkperformancesystems
6 posts audited · 8 claims analysed
Science evidence grade
Based on 8 claims across 6 audits
4
Supported
50%
2
Overstated
25%
0
Misleading
0%
2
No Evidence
25%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @darkperformancesystems claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
50%
4 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
50%
4 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(6 posts)
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
While the claims touch on legitimate areas of metabolic peptide research, the specific assertions about Retatrutide lack definitive human clinical validation. The broader claim about GLP-1's appetite-suppressing effects is well-supported by existing scientific literature.
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
Retatrutide represents an emerging multi-receptor approach in metabolic treatment, with promising early clinical evidence of its efficacy in weight management and glycemic control. While initial results are encouraging, more long-term studies are needed to fully establish its therapeutic profile.
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
The claim about R*trutide having a unique weight loss mechanism lacks scientific substantiation. No peer-reviewed research or clinical trials were found to support the proposed mechanism or weight loss effects. Further research and rigorous clinical studies would be required to validate any specific claims about this compound.
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
The claim about Retrutide having a unique weight loss mechanism lacks scientific substantiation at this time. No specific clinical trials or peer-reviewed studies were found to support the creator's assertion about this peptide's distinctive weight loss properties. Further research and clinical investigation would be needed to validate any unique mechanisms.
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
The claim about R*trutide's unique weight loss mechanism lacks scientific substantiation. Without published research or clinical trials, there is insufficient evidence to evaluate the proposed mechanism or potential effectiveness. Further rigorous scientific investigation would be required to validate any specific claims about this compound.
“R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.”
The scientific literature provides strong evidence supporting retatrutide's multi-receptor mechanism. A comprehensive Phase 2 human trial demonstrated the peptide's ability to simultaneously engage GLP-1, GIP, and glucagon receptors, with meaningful clinical outcomes in type 2 diabetes management.
Audit another post from @darkperformancesystems
Paste their social post link to add a new audit